Smt. Kanuri Santhamma Vitreoretinal Center, L V Prasad Eye Institute, Hyderabad, India.
Retina. 2012 Nov-Dec;32(10):2001-5. doi: 10.1097/IAE.0b013e3182625c1d.
To evaluate the efficacy of intravitreal anti-vascular endothelial growth factor monotherapy in the treatment of naive subretinal neovascular membrane (SRNVM) secondary to macular telangiectasia (Mactel) Type 2.
A retrospective chart review of consecutive patients with naive SRNVM secondary to Mactel who were examined between January 2007 and April 2011 was performed. Eyes with diabetic retinopathy, age-related macular degeneration, or any other macular pathology were excluded. Demographic data, medical history, and ocular history were recorded. The mean change in best-corrected visual acuity at the final visit was the primary outcome measure. The mean number of intravitreal injections, retinal thickness on optical coherence tomography, and intraocular pressure were the secondary outcomes.
A total of 16 eyes of 16 patients were included in the study. Of 16 eyes, 4 were treated with intravitreal ranibizumab monotherapy and 12 with intravitreal bevacizumab monotherapy. The average follow-up duration was 12 months (range, 3-43 months). The mean baseline visual acuity was 0.17 ± 0.16 (Snellen equivalent 20/120) (range, 0.001-0.5), and the mean final visual acuity was 0.27 ± 0.14 (Snellen equivalent 20/70) (range, 0.05-0.66), and this difference was statistically significant (P = 0.02). The mean number of intravitreal injections was 1.9 (range, 1-3), and there were no injection-related complications.
Intravitreal anti-vascular endothelial growth factor monotherapy appears to be effective and safe in treatment-naive SRNVM secondary to Mactel.
评估玻璃体内抗血管内皮生长因子单药治疗 2 型黄斑毛细血管扩张症（Mactel）继发的初发性脉络膜视网膜新生血管膜（SRNVM）的疗效。
对 2007 年 1 月至 2011 年 4 月期间连续检查的 16 例 Mactel 继发的初发性 SRNVM 患者进行回顾性图表审查。排除糖尿病视网膜病变、年龄相关性黄斑变性或任何其他黄斑病变的患者。记录人口统计学资料、病史和眼部病史。主要观察指标为最终随访时最佳矫正视力的平均变化。次要观察指标为平均玻璃体内注射次数、光学相干断层扫描视网膜厚度和眼内压。
本研究共纳入 16 例患者的 16 只眼。其中 4 只眼接受玻璃体内雷珠单抗单药治疗，12 只眼接受玻璃体内贝伐单抗单药治疗。平均随访时间为 12 个月（范围 3-43 个月）。平均基线视力为 0.17 ± 0.16（Snellen 等效值 20/120）（范围 0.001-0.5），平均最终视力为 0.27 ± 0.14（Snellen 等效值 20/70）（范围 0.05-0.66），差异具有统计学意义（P=0.02）。平均玻璃体内注射次数为 1.9（范围 1-3），无注射相关并发症。
玻璃体内抗血管内皮生长因子单药治疗似乎对 Mactel 继发的初发性 SRNVM 有效且安全。
